Our Story

We provide personalized nutrition and actionable insights that allow you to live healthier and maintain normal blood sugar levels. Discover surprising food possibilities, while living your life with smarter nutritional and activity choices. We do this by studying your individual metrics and gut microbiome – that vast collection of bacteria that you host. Turns out your microbiome has a big impact on your health, and we translate your unique gut bacteria into personalized actionable insights.

The product is based on a five year research conducted by Prof. Eran Segal and Dr. Eran Elinav from the Weizmann Institute of Science in Israel; the research was funded solely by the Weizmann Insitute of Science and upon its completion, the research technology was licensed to DayTwo. The research results were published in the journal Cell and the Research Video can be found here.

Our Team

Marius Nacht

Board Member, Co-Founder

Marius is chairman at Check Point Software (NASDAQ: CHKP), and has previously held various senior vice president roles. He is currently an angel investor, co-founder and board member of several IT and healthcare startups. Marius earned a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem (Talpiot) and a M.Sc. in Electrical Engineering and Communication Systems from Tel Aviv University.)

Yuval Ofek

Chairman, Co-Founder

Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of

Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Dr. Eran Elinav

Scientific Consultant, MD PhD

Eran is a senior scientist leading a research group at the Immunology Department of the Weizmann Institute of Science. His group focuses on deciphering the molecular basis of host-microbiome interactions and their effects on health and disease, with a goal of personalizing medicine and nutrition.
Dr. Elinav published over 110 publications, and received several awards for his work, including the 2013 Alon prize, and the 2015 Rappaport prize, awarded annually to one scientist for outstanding accomplishments in the field of biomedical research.

Before joining the Weizmann Institute, Dr. Elinav held an independent research position as a physician-Scientist at the Institute for Gastroenterology and Liver disease at the Tel Aviv Sourasky Medical Center.Dr. Elinav completed his medical doctor’s (MD) degree at the Hebrew University of Jerusalem Hadassah Medical Center summa cum laude, followed by a clinical internship, residency in internal medicine, and a clinical and research position at the Tel Aviv Medical Center Gastroenterology institute. He received a PhD in immunology from the Weizmann Institute of Science, followed by a postdoctoral fellowship at Yale University School of Medicine.

Prof. Eran Segal

Scientific Consultant, PhD

Eran is a Professor at the Department of Computer Science and Applied Mathematics at the Weizmann Institute of Science, heading a lab with a multi-disciplinary team of computational biologists and experimental scientists in the area of Computational and Systems biology. His research focuses on studying the relationship between nutrition, health and gut microbes in human individuals.
Prof. Segal published over 110 publications, and received several awards and honors for his work, including the EMBO young investigator award, the Michael Bruno award, and the Overton prize, awarded annually by the International Society for Bioinformatics (ICSB) to one scientist for outstanding accomplishments in the field of computational biology. He was recently elected as an EMBO member and as a member of the young Israeli academy of science.

Before joining the Weizmann Institute, Prof. Segal held an independent research position at Rockefeller University, New York. Prof. Segal was awarded a B.Sc. in Computer Science summa cum laude in 1998, from Tel-Aviv University, and a PhD. in Computer Science and Genetics in 2004, from Stanford University.

Yuval Ofek

Chairman, Co-Founder

Yuval founded dbMotion Ltd., in 2004 and was its Chairman and CEO until acquired by Allscripts Healthcare, a leading US EMR company, in 2013. Prior to forming dbMotion, Yuval was involved in several startups in the Boston area and held various positions ranging from CTO, EVP and Chairman. Yuval was president of the Customer Experience Management division of Nice Systems and Vice President of

Enterprise Storage Development at EMC Corporation in Boston, Massachusetts. Yuval holds 82 U.S. and European patents in storage and networking. He has a bachelor’s degree in Electrical Engineering from the Technion – Israel Institute of Technology.

Lihi Segal

CEO, Co-Founder

Lihi Segal co-founded DayTwo in 2015 to bring personalized health solutions based on the gut microbiome into the consumer mainstream. She is experienced in leading business and financial operations having been COO and CFO of Sisense, a provider of business intelligence and analytics software, before starting DayTwo.

For more than fifteen years prior to that she has held senior roles in a number of businesses, from startups to large public enterprises. She is a certified Lawyer, has an LLB from the Tel-Aviv University and an MBA from Northwestern University, USA.

Ami Tavory

Head of Research

Ami was the chief data scientist at Qwilt, where he led the effort to efficiently mine massive amounts of video traffic for predicting usage patterns. Before that he was a Research Team Leader at Final, where he was involved in applied research and implementation of statistical arbitrage algorithms. Prior to that he was a Research Staff Member and Team Leader at IBM, where he conducted research in

distributed storage problems, specifically highly-parallel object-based storage and distributed error-correcting codes. Ami holds a PhD in the field of financial information theory from the EE faculty of Tel Aviv university, as well as an M.Sc in the field of error-correcting codes, and a B.Sc in computer engineering – both also from the EE faculty of Tel Aviv university, and with honors. He has published and lectured in the fields of financial information theory, error correcting codes, and practical high-performance scientific computing, and has contributed to several open source projects.

Davidi Bachrach

COO

Davidi was the VP Product Management, Population Health in Allscripts where he managed the product life cycle from strategic planning and product roadmap to tactical activities, specifying and prioritizing market requirements for the Population Health products. Prior to Allscripts, he was the VP Professional Services for dbMotion Ltd., managed the company enterprise-wide projects in North America,

planning and implementation of dbMotion technologies at customer sites, developing product assimilation methodologies and providing the technical focal point for system integration, customer support and training. He has a BSc degree in Industrial Engineering and MBA degree from the Ben Gurion University in Israel

Lior Froimovich

VP of Research and Development

Lior was the VP of research and development at Mobli, where he managed the product development, quality, production health and scalability to produce and maintain several high scale social applications used by millions of users. Lior also led an agile process of building the architecture of big data social platforms, cloud based solutions, multi-platforms mobile and web technologies. Before that he was VP of research and development at Odysii producing

a large scale SAAS targeted suggestive selling platform using Real-time Transaction analysis. Lior holds a B.Sc in software engineering from the Technion – Israel Institute of Technology.

Prof. Ari Shamiss

Prof. Ari Shamiss is the CEO of Sheba General Hospital, a 1400 bed acute care medical center in Israel. Prof. Shamiss holds MD from the Technion Institute and MPA from Harvard University. He is certified in Internal Medicine, Hypertension and Healthcare Management and he is a Professor in Tel Aviv University on these disciplines with more than 60 published scientific papers.Prof. Shamiss was the Surgeon General for the Israel Air Force (Col. Ret.) and the Director of its Aeromedical Institute and he is a graduate in excellence of the US Navy Aerospace Medical Institute.Prof.

Shamiss is involved in numerous global business projects including healthcare technologies, healthcare management services and infrastructure, investment consultancy, Healthcare Information Technology, homeland security, and emergency preparedness. (Apr 2016)

Steven Schwartz

As Senior Vice President, Strategy and Corporate Development at Healthways [Nasdaq: HWAY], Steve is responsible for company strategy, management of emerging businesses, as well as growth via partnerships, and M & A. Steve has more than 25 years of experience in building high-growth companies in healthcare and information technology, joining Healthways from Silicon Valley’s 23andMe. As VP of Business Development and Strategy at 23andMe he was instrumental in accelerating the company’s business-to-business growth

strategy with life sciences companies, health systems, health plans, and retailers. Steve has been a leading innovator and evangelist in the application of information technology in healthcare; from the adoption of mobile technologies, medical records, and giving consumers access to their data; to the use of big data and genomics in drug development and clinical decision support. Prior to 23andMe, Mr. Schwartz was Senior Vice President of Business Development at Allscripts, where he helped lead the company’s dramatic growth for more than a decade, securing strategic partnerships with some of the world’s leading information technology and life sciences companies. Schwartz also spent more than 10 years at LabCorp, contributing to its emergence as the nation’s leading clinical laboratory companies.